UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

Environment and lupus-related diseases

Lupus, 2012-03, Vol.21 (3), p.241-250

2012

Volltextzugriff (PDF)

OARSI-FDA initiative: defining the disease state of osteoarthritis

Osteoarthritis and cartilage, 2011-05, Vol.19 (5), p.478-482

2011

Volltextzugriff (PDF)

Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

Journal of the European Academy of Dermatology and Venereology, 2022-04, Vol.36 (4), p.602-609

2022

Volltextzugriff (PDF)

Efficacy and safety of the Janus kinase 1 inhibitor PF‐04965842 in patients with moderate‐to‐severe psoriasis: phase II, randomized, double‐blind, placebo‐controlled study

British journal of dermatology (1951), 2018-07, Vol.179 (1), p.54-62

2018

Volltextzugriff (PDF)

Prolactin rescues and primes autoreactive B cells directly and indirectly through dendritic cells in B6.Sle3 mice

Clinical and experimental immunology, 2013-05, Vol.172 (2), p.311-320

2013

Volltextzugriff (PDF)

Monoclonal antibody against macrophage colony‐stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus

Clinical and experimental immunology, 2016-02, Vol.183 (2), p.258-270

2016

Volltextzugriff (PDF)

AB0572 Meta-analysis of the key rheumatoid arthritis (RA) disease activity endpoints in patients treated with B-cell depleting therapies

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.671-671

2013

Volltextzugriff (PDF)

Sex hormones and SLE: influencing the fate of autoreactive B cells

Current topics in microbiology and immunology, 2006, Vol.305, p.67

2006

Volltextzugriff (PDF)

LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S184-S184

2024

Volltextzugriff (PDF)

A walking model to assess the onset of analgesia in osteoarthritis knee pain

Osteoarthritis and cartilage, 2010-05, Vol.18 (5), p.646-653

2010

Volltextzugriff (PDF)

110 Natural history of keloids: A sociodemographic analysis using structured and unstructured data

Journal of investigative dermatology, 2023-11, Vol.143 (11), p.S351

2023

Volltextzugriff (PDF)

290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S50-S50

2024

Volltextzugriff (PDF)

LB944 The efficacy and safety of multiple dose levels of the PDE4 inhibitor PF-07038124 in participants 12 years and older with mild-to-moderate atopic dermatitis and mild-to-severe plaque psoriasis

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S165-S165

2024

Volltextzugriff (PDF)

1187 Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, reduces immune biomarkers in active lesions and increases melanocyte products in stable lesions in patients with non-segmental vitiligo (NSV)

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S204-S204

2023

Volltextzugriff (PDF)

1215 Ritlecitinib, an oral dual JAK3/TEC family kinase inhibitor, induces differential changes in immunological protein levels across Fitzpatrick skin types (FST) in patients with active nonsegmental vitiligo (NSV)

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S208-S208

2023

Volltextzugriff (PDF)

Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes

Immunology Letters, 2005-11, Vol.101 (2), p.123-143

2005

Volltextzugriff (PDF)

A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States

Clinical, cosmetic and investigational dermatology, 2020-01, Vol.13, p.259-266

2020

Volltextzugriff (PDF)

OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i16-i16

2024

Volltextzugriff (PDF)

554 The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD)

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.S94-S94

2018

Volltextzugriff (PDF)

544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

Journal of investigative dermatology, 2019-05, Vol.139 (5), p.S94-S94

2019

Volltextzugriff (PDF)

Prolactin rescues and primes autoreactive B cells directly and indirectly through dendritic cells in B6. Sle3 mice

Clinical and experimental immunology, 2013-04, Vol.172 (2), p.311-320

2013

Volltextzugriff (PDF)

OP33 Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S030-S031

2021

Volltextzugriff (PDF)

LB1485 Prevalence of alopecia areata in the United States from a large cross-sectional survey

Journal of investigative dermatology, 2018-09, Vol.138 (9), p.B3-B3

2018

Volltextzugriff (PDF)

517 Effects of the oral janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD)

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.S88-S88

2018

Volltextzugriff (PDF)

56 PROLACTIN ALTERS BCR-MEDIATED APOPTOSIS AND RECEPTOR EDITING

Journal of investigative medicine, 2007-03, Vol.55 (2), p.S357-S357

2007

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(43)
Humans
(36)
Female
(22)
Male
(17)
Animals
(16)
Adult
(15)
Middle Aged
(13)
Rheumatology
(11)
Biological And Medical Sciences
(9)
Immunology
(9)
Lupus Erythematosus, Systemic - Immunology
(9)
B-Lymphocytes - Immunology
(8)
Medical Sciences
(8)
Mice
(8)
Physical Sciences
(8)
Technology
(8)
Double-Blind Method
(7)
Aged
(4)
Dermatology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Environment and lupus-related diseases

OARSI-FDA initiative: defining the disease state of osteoarthritis

Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

Efficacy and safety of the Janus kinase 1 inhibitor PF‐04965842 in patients with moderate‐to‐severe psoriasis: phase II, randomized, double‐blind, placebo‐controlled study

Prolactin rescues and primes autoreactive B cells directly and indirectly through dendritic cells in B6.Sle3 mice

Monoclonal antibody against macrophage colony‐stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus

AB0572 Meta-analysis of the key rheumatoid arthritis (RA) disease activity endpoints in patients treated with B-cell depleting therapies

Sex hormones and SLE: influencing the fate of autoreactive B cells

LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties

A walking model to assess the onset of analgesia in osteoarthritis knee pain

110 Natural history of keloids: A sociodemographic analysis using structured and unstructured data

290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers

LB944 The efficacy and safety of multiple dose levels of the PDE4 inhibitor PF-07038124 in participants 12 years and older with mild-to-moderate atopic dermatitis and mild-to-severe plaque psoriasis

1187 Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, reduces immune biomarkers in active lesions and increases melanocyte products in stable lesions in patients with non-segmental vitiligo (NSV)

1215 Ritlecitinib, an oral dual JAK3/TEC family kinase inhibitor, induces differential changes in immunological protein levels across Fitzpatrick skin types (FST) in patients with active nonsegmental vitiligo (NSV)

Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes

A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States

OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella study

554 The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD)

544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

Prolactin rescues and primes autoreactive B cells directly and indirectly through dendritic cells in B6. Sle3 mice

OP33 Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study

LB1485 Prevalence of alopecia areata in the United States from a large cross-sectional survey

517 Effects of the oral janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD)

56 PROLACTIN ALTERS BCR-MEDIATED APOPTOSIS AND RECEPTOR EDITING

Suchergebnisse filtern